Zinbryta Fails to Prevent RRMS from Worsening After Patient Gets Off Tysabri, Case Study Shows

Zinbryta (daclizumab) may not be the best follow-up therapy for relapsing–remitting multiple sclerosis patients who stop taking Tysabri (natalizumab) for safety reasons, a case study suggests.

An article on the 25-year-old patient’s case, titled “Disease reactivation after switching from natalizumab to daclizumab,” was published in the Journal of Neurology.

Discontining Biogen’s Tysabri leads to many patients’ disease worsening. The question doctors face is what treatment to prescribe after Tysabri. One possibility is Zinbryta.

The U.S. Food and Drug Administration and European Union approved it as therapy for active RRMS cases in 2016.  Biogen and AbbVie market the monoclonal antibody, which targets the CD25 protein that scientists have linked to MS.

Researchers studied the 25-year-old patient’s case for clues about whether Zinbryta could benefit MS patients who discontinue Tysabri.

continue